Effective Cannabis | Research & Blog
A central nervous system disorder (neurological disorder) in which nerve cell activity in the brain becomes disrupted, causing seizures or periods of unusual behavior, sensations and sometimes loss of consciousness. Seizure symptoms can vary widely. … However, a single seizure doesn’t mean you have epilepsy.
In 2013, Survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. A parent survey was presented to a Facebook group dedicated to sharing information about the use of cannabis to treat their child’s seizures. Background: Survey consisted of 24 questions that measured clinical factors, including diagnosis and seizure types. As a result .. Read More
In 2013, A study showed cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Background: The anticonvulsant profiles of two CBDV BDSs were evaluated in three animal models of acute seizure. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792005/
in 2013, survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. BACKGROUND: The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol-enriched cannabis to treat their child’s seizures. You can read the full article here => https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157067/
In 2015, Cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. With 117 parents. BACKGROUND: We sought to document the experiences of children with IS and/or LGS who have been treated with CBD-enriched cannabis preparations. We conducted a brief online survey of parents who administered CBD-enriched cannabis .. Read More
In 2017, Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome BACKGROUND. Multinational, randomized, double-blind trial of adjunctive cannabidiol versus placebo in children and young adults 2 to 18 years of age with the Dravet syndrome whose seizures were not controlled by their current antiepileptic-drug regimen. The trial comprised a 4-week baseline period, a 14-week .. Read More
